Peptides in Pain Management: BPC-157, Risks, Reality, and the Business of Regenerative Medicine

Peptides like BPC-157 have exploded in popularity across regenerative medicine, sports medicine, and cash-based pain practices — but does the science support the hype? In this episode of PainExam, Dr. David Rosenblum takes a critical, evidence-based look at BPC-157 and other peptidesin pain management, examining: The biological rationale behind peptide therapy Preclinical and early human evidence for pain and tissue healing Regulatory status and safety concerns Ethical, legal, and marketing risks for physicians How peptides are currently being incorporated — and monetized — in pain practices This episode is designed to help clinicians separate science from marketing, and to approach peptide therapies with appropriate caution and professionalism.